The overall survival of patients, based on the survival data from “The cancer genome Atlas (TCGA)” from the STAD study (TCGA Stomach Cancer), shows a significant positive effect (P=0.004) in those patients with a lower expression of Claudin-9. Here, CLDN9 is linked to digestive system neoplasm.